Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTN3379 alone or in combination in advanced tumors
NCT02014909Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Jan 2014
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cdx-3379 in solid tumor (advanced stage), head and neck cancer (HNC), colorectal cancer (CRC) and 4 more (5 arms), sponsored by Celldex Therapeutics. Primary endpoint: Dose limiting toxicities. Started Jan 2014; status: completed.
02
Drugs
cdx-3379
03
Conditions
solid tumor (advanced stage)head and neck cancer (HNC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT02014909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014909.